Corrigendum to ‘MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC’ [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450, (S1556086423023481), (10.1016/j.jtho.2023.10.017)]

Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa, Chie Kikutake, Mikita Suyama, Asato Hashinokuchi, Kazuki Takada, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Tetsuya Mitsudomi, Aaron N. Hata, Donald Kufe

Research output: Contribution to journalComment/debatepeer-review

Abstract

The published version of this article contained an error in Fig. 4C, which does not affect the conclusions of the research. Using Proofig AI following publication, the authors found that the same image for p-EGFR was inadvertently included in Figs. 4A and 4C. The corrected version for Fig. 4C is provided below.[Figure

Original languageEnglish
Pages (from-to)399
Number of pages1
JournalJournal of Thoracic Oncology
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 2025

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Corrigendum to ‘MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC’ [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450, (S1556086423023481), (10.1016/j.jtho.2023.10.017)]'. Together they form a unique fingerprint.

Cite this